Target intelligence / Profile preview

Immunoglobulin kappa variable 6-21 (IGKV6-21)

Target
IGKV6-21
Molecular classification
Immunoglobulin variable domain, Immunoglobulin light chain variable region, Other
01

Overview

Immunoglobulin kappa variable 6-21 (IGKV6-21) is a gene segment encoding the variable region of the kappa light chain of immunoglobulins. As part of the immune system’s humoral response, the variable region contributes to antigen recognition and binding specificity of antibodies produced by B lymphocytes. The IGKV6-21 gene segment participates in V-(D)-J recombination, the process that assembles functional immunoglobulin molecules capable of identifying and binding to specific antigens. Most references identify IGKV6-21 as non-functional (also termed an ORF, or open reading frame), suggesting it is not typically used in productive antibody synthesis but may be rearranged in some cases. It does not serve as a classical therapeutic target or biomarker on its own, and no drugs directly target this gene segment. The overall family is critically important for the diversity and specificity of antibodies, but IGKV6-21 itself holds significance mainly as a member of the kappa light chain gene repertoire. IGKV6-21 is located at chromosome 2p11.2 within the IGK locus, which contains many similar gene segments, and is a paralog of IGKV6D-21. It is not a receptor, enzyme, transporter, or transcription factor. Common use in biomedical research focuses on functional immunoglobulin genes rather than specific variable region gene segments. For structured annotation, IGKV6-21 should not be classified as a classical drug target or disease biomarker, but only as part of the immunoglobulin gene family.

Other names
Immunoglobulin kappa variable 6-21IGKV6-21IGKV621KV621A26
02

Mechanism of action

Not applicable (gene segment not directly targeted by therapies)

03

Biological functions

Immune responseAntigen recognitionAntibody diversityHumoral immunity
04

Disease associations

Other (not directly disease causing, but part of immune gene variability)
05

Safety considerations

None specific to IGKV6-21; immunoglobulin genes in general may be involved in autoimmune/lymphoproliferative disorders

Beyond the preview

Go deeper on Immunoglobulin kappa variable 6-21 (IGKV6-21).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin kappa variable 6-21 (IGKV6-21).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call